Core Viewpoint - BeiGene's stock price increased nearly 3% in pre-market trading following the announcement of conditional approval for its self-developed BCL2 inhibitor, SOTYKTU (sotatercept), by the National Medical Products Administration (NMPA) for specific cancer treatments [1] Group 1: Drug Approval and Market Impact - BeiGene announced that its BCL2 inhibitor, SOTYKTU, received conditional approval from the NMPA for treating adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received at least one systemic treatment including a BTK inhibitor [1] - The approval also covers adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have undergone at least two systemic treatments, including a BTK inhibitor, making SOTYKTU the first and only BCL2 inhibitor approved for MCL treatment in China [1] - Following the news, BeiGene's stock price rose to $329.5 in pre-market trading, reflecting a 2.86% increase [2] Group 2: Stock Performance Metrics - The closing price of BeiGene's stock was $320.00, with a pre-market price of $329.50, indicating a significant upward movement [2] - The stock's trading volume was 293,100 shares, with a market capitalization of approximately $37.966 billion [2] - The stock has a 52-week high of $385.22 and a low of $174.74, showcasing its volatility in the market [2]